The Global Osteoporosis Treatment Market Size gathered USD 12.2 Billion in 2021 and is set to garner a market size of USD 17.1 Billion by 2030 growing at a CAGR of 3.9% from 2022 to 2030.
Osteoporosis treatment is a collection of measures aimed at preventing fractures and increasing bone density in people suffering from osteoporosis, a condition characterized by weak and fragile bones. It is significant because osteoporosis can cause bones to become so fragile that even minor falls or impacts can result in fractures, which can be debilitating and have a negative impact on quality of life. Early detection and treatment can help to slow or even stop the progression of osteoporosis, lowering the risk of fractures. Treatments can also help to relieve pain, improve mobility, and lower the risk of disability. Treatment may even help to increase bone density and strength in some cases, lowering the risk of future fractures. Because osteoporosis is a progressive disease, it is critical to begin treatment as soon as possible for the best results.
Osteoporosis Treatment Market Report Statistics
- Global osteoporosis treatment market revenue is estimated to reach USD 17.1 billion by 2030 with a CAGR of 3.9% from 2022 to 2030
- North America osteoporosis treatment market value gathered more than USD 4.8 billion in 2021
- Asia-Pacific osteoporosis treatment market growth will record a CAGR of more than 4% from 2022 to 2030
- Among drug classes, the bisphosphonate sub-segment collected around 40% share in 2021
- Based on distribution channel, the hospital pharmacies sub-segment achieved US$ 5.6 billion in revenue in 2021
- The growing popularity of personalized medicine is a popular osteoporosis treatment market trend that drives the industry demand
Global Osteoporosis Treatment Market Dynamics
Market Drivers
- Growing elderly population
- Increased occurrence of osteoporosis
- Advancement in drug development technology
Market Restraints
- High cost of treatments
- Lack of awareness and diagnostic tools in developing countries
- Stringent regulatory requirements
Market Opportunities
- Government initiatives and strong support
- Rising economies and healthcare expenditure
Osteoporosis Treatment Market Report Coverage
| Market |
Osteoporosis Treatment Market |
| Osteoporosis Treatment Market Size 2021 |
USD 12.2 Billion |
| Osteoporosis Treatment Market Forecast 2030 |
USD 17.1 Billion |
| Osteoporosis Treatment Market CAGR During 2022 - 2030 |
3.9% |
| Osteoporosis Treatment Market Analysis Period |
2018 - 2030 |
| Osteoporosis Treatment Market Base Year |
2021 |
| Osteoporosis Treatment Market Forecast Data |
2022 - 2030 |
| Segments Covered |
By Drug Class, By Route of Administration, By Distribution Channel, And By Geography
|
| Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled |
Amgen Inc., Asahi Kasei Corporation, DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GSK plc., Ligand Pharmaceuticals Incorporated, Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc.
|
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Covid-19 Analysis, Regulation Analysis |
Osteoporosis Treatment Market Growth Factors
As the population of older adults grows, so does the prevalence of osteoporosis, driving demand for treatments. Increased public awareness of the condition, as well as the advantages of early detection and treatment, are driving growth in the osteoporosis treatment market. Technological advancements and drug development are expected to drive up demand in the coming years. The development of new, more effective osteoporosis medications, as well as advancements in bone density testing, is also driving the market growth. Government support and initiatives aimed at improving bone health and lowering the incidence of osteoporosis-related fractures are also fueling the market growth.
However, many osteoporosis treatments, particularly medications, can be prohibitively expensive for some patients. Some developing countries may have limited access to diagnostic tools and a lack of public awareness about osteoporosis, which can limit the market growth. The osteoporosis treatment market is highly competitive, with generic drugs potentially reducing demand for more costly brand treatments. Furthermore, the approval process for new osteoporosis treatments is stringent, which may limit the introduction of new products and market growth.
Growing economies and healthcare expenditures are two significant factors that are expected to generate numerous growth opportunities between 2022 and 2030. As economies grow and healthcare spending rises, so does the market for osteoporosis treatments. Furthermore, the prevalence of osteoporosis is increasing: As people live longer lives, the prevalence of osteoporosis rises, creating a greater need for treatment.
Osteoporosis Treatment Market Segmentation
The worldwide osteoporosis treatment market is categorized based on drug class, route of administration, distribution channel, and geography.
Osteoporosis Treatment Market By Drug Class
- Bisphosphonate
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Replacement Therapy
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- RANK ligand (RANKL) Inhibitor
- Selective Estrogen Receptor Modulator (SERMs)
According to an osteoporosis treatment industry analysis, the bisphosphonate sub-segment generate the largest revenue in 2021. Bisphosphonates are a commonly used drug class for the treatment of osteoporosis and be effective in reducing the risk of fractures and increasing bone density. Bisphosphonates work by inhibiting the activity of cells that break down bone, thereby slowing down bone loss. They are often used as first-line treatments for osteoporosis and are well-tolerated by most patients. Examples of bisphosphonates include alendronate, ibandronate, risedronate, and zoledronic acid. The high revenue generated by bisphosphonates is a testament to their efficacy and popularity as a treatment option for osteoporosis.
Osteoporosis Treatment Market By Route of Administration
In the osteoporosis treatment market, the oral route of administration has gained significant traction. This is most likely due to the ease and convenience of taking oral medications, as well as the lower cost of oral medications compared to intravenous treatments. Bisphosphonates, a common class of drugs used to treat osteoporosis, are typically taken orally. The popularity of oral bisphosphonates and other osteoporosis medications has fueled growth in the oral treatment market. However, it is important to note that intravenous treatments for osteoporosis, such as zoledronic acid, can also be effective and may be favored by some patients or healthcare providers.
Osteoporosis Treatment Market By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies & Stores
- Online Pharmacies
As per the osteoporosis treatment market forecast, hospital pharmacies are a leading distribution channel for osteoporosis treatments, and they have generated significant revenue in the osteoporosis treatment market. This is since many patients with osteoporosis are treated in a hospital setting, particularly for intravenous treatments or treatment after a fracture. Hospital pharmacies are well-equipped to provide patients with the medications they require, as well as the infrastructure to manage inventory, fill prescriptions, and ensure that patients receive the correct medication dose.
Osteoporosis Treatment Market Regional Outlook
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
The Middle East & Africa
- South Africa
- GCC Countries
- Rest of the Middle East & Africa (ME&A)
Osteoporosis Treatment Market Regional Analysis
The North American osteoporosis treatment market is mature and well-established, with high levels of demand for effective osteoporosis treatments and strong healthcare infrastructure. North America has a large and aging population, with many people at risk for and in need of osteoporosis treatment. As a result, the North American osteoporosis treatment market is one of the world's largest and most profitable.
The Asia-Pacific osteoporosis treatment market is rapidly expanding, driven by rising levels of demand for effective osteoporosis treatments and expanding healthcare infrastructure. The Asia-Pacific region has a large and aging population, with many people at risk for and in need of osteoporosis treatment. Furthermore, the region's economy is rapidly expanding, which is driving growth in the healthcare sector and intensifying access to medical services and treatments.
Osteoporosis Treatment Market Players
Some of the leading osteoporosis treatment companies include Amgen Inc., Asahi Kasei Corporation, DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GSK plc., Ligand Pharmaceuticals Incorporated, Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc.
CHAPTER 1. Industry Overview of Osteoporosis Treatment Market
1.1. Definition and Scope
1.1.1. Definition of Osteoporosis Treatment
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Osteoporosis Treatment Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Osteoporosis Treatment Market By Drug Class
1.2.3. Osteoporosis Treatment Market By Route of Administration
1.2.4. Osteoporosis Treatment Market By Distribution Channel
1.2.5. Osteoporosis Treatment Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Osteoporosis Treatment Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Osteoporosis Treatment Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2021
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2021
4.2. R&D Status of Major Manufacturers in 2021
CHAPTER 5. Osteoporosis Treatment Market By Drug Class
5.1. Introduction
5.2. Osteoporosis Treatment Market Revenue By Drug Class
5.2.1. Osteoporosis Treatment Market Revenue (USD Billion) and Forecast, By Drug Class, 2018-2030
5.2.2. Bisphosphonate
5.2.2.1. Bisphosphonate Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.2.2. Alendronate
5.2.2.2.1. Alendronate Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.2.3. Risedronate
5.2.2.3.1. Risedronate Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.2.4. Ibandronate
5.2.2.4.1. Ibandronate Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.2.5. Zoledronic Acid
5.2.2.5.1. Zoledronic Acid Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.2.6. Others
5.2.2.6.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.3. Calcitonin
5.2.3.1. Calcitonin Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.4. Hormone Replacement Therapy
5.2.4.1. Hormone Replacement Therapy Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.5. Selective Estrogen Receptor Modulators (SERMs)
5.2.5.1. Selective Estrogen Receptor Modulators (SERMs) Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.6. Parathyroid Hormone-Related Protein (PTHrP) Analog
5.2.6.1. Parathyroid Hormone-Related Protein (PTHrP) Analog Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.7. Rank Ligand (RANKL) Inhibitor
5.2.7.1. Rank Ligand (RANKL) Inhibitor Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 6. Osteoporosis Treatment Market By Route of Administration
6.1. Introduction
6.2. Osteoporosis Treatment Market Revenue By Route of Administration
6.2.1. Osteoporosis Treatment Market Revenue (USD Billion) and Forecast, By Route of Administration, 2018-2030
6.2.2. Injectables
6.2.2.1. Injectables Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
6.2.3. Oral
6.2.3.1. Oral Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
6.2.4. Others
6.2.4.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 7. Osteoporosis Treatment Market By Distribution Channel
7.1. Introduction
7.2. Osteoporosis Treatment Market Revenue By Distribution Channel
7.2.1. Osteoporosis Treatment Market Revenue (USD Billion) and Forecast, By Distribution Channel, 2018-2030
7.2.2. Retail Pharmacies & Stores
7.2.2.1. Retail Pharmacies & Stores Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
7.2.3. Hospitals Pharmacies
7.2.3.1. Hospitals Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
7.2.4. Online Pharmacies
7.2.4.1. Online Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 8. North America Osteoporosis Treatment Market By Country
8.1. North America Osteoporosis Treatment Market Overview
8.2. U.S.
8.2.1. U.S. Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
8.2.2. U.S. Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
8.2.3. U.S. Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
8.3. Canada
8.3.1. Canada Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
8.3.2. Canada Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
8.3.3. Canada Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
8.4. North America PEST Analysis
CHAPTER 9. Europe Osteoporosis Treatment Market By Country
9.1. Europe Osteoporosis Treatment Market Overview
9.2. U.K.
9.2.1. U.K. Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
9.2.2. U.K. Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
9.2.3. U.K. Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
9.3. Germany
9.3.1. Germany Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
9.3.2. Germany Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
9.3.3. Germany Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
9.4. France
9.4.1. France Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
9.4.2. France Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
9.4.3. France Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
9.5. Spain
9.5.1. Spain Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
9.5.2. Spain Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
9.5.3. Spain Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
9.6. Rest of Europe
9.6.1. Rest of Europe Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
9.6.2. Rest of Europe Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
9.6.3. Rest of Europe Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
9.7. Europe PEST Analysis
CHAPTER 10. Asia-Pacific Osteoporosis Treatment Market By Country
10.1. Asia-Pacific Osteoporosis Treatment Market Overview
10.2. China
10.2.1. China Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
10.2.2. China Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
10.2.3. China Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
10.3. Japan
10.3.1. Japan Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
10.3.2. Japan Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
10.3.3. Japan Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
10.4. India
10.4.1. India Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
10.4.2. India Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
10.4.3. India Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
10.5. India Australia
10.5.1. Australia Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
10.5.2. Australia Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
10.5.3. Australia Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
10.6. South Korea
10.6.1. South Korea Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
10.6.2. South Korea Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
10.6.3. South Korea Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
10.7.2. Rest of Asia-Pacific Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
10.7.3. Rest of Asia-Pacific Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
10.8. Asia-Pacific PEST Analysis
CHAPTER 11. Latin America Osteoporosis Treatment Market By Country
11.1. Latin America Osteoporosis Treatment Market Overview
11.2. Brazil
11.2.1. Brazil Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
11.2.2. Brazil Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
11.2.3. Brazil Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
11.3. Mexico
11.3.1. Mexico Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
11.3.2. Mexico Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
11.3.3. Mexico Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
11.4. Rest of Latin America
11.4.1. Rest of Latin America Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
11.4.2. Rest of Latin America Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
11.4.3. Rest of Latin America Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
11.5. Latin America PEST Analysis
CHAPTER 12. Middle East & Africa Osteoporosis Treatment Market By Country
12.1. Middle East & Africa Osteoporosis Treatment Market Overview
12.2. GCC
12.2.1. GCC Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
12.2.2. GCC Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
12.2.3. GCC Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
12.3. South Africa
12.3.1. South Africa Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
12.3.2. South Africa Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
12.3.3. South Africa Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
12.4.2. Rest of Middle East & Africa Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Route of Administration, 2018-2030
12.4.3. Rest of Middle East & Africa Osteoporosis Treatment Market Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
12.5. Middle East & Africa PEST Analysis
CHAPTER 13. Player Analysis Of Osteoporosis Treatment Market
13.1. Osteoporosis Treatment Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Osteoporosis Treatment Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. Company Profile
14.1. Amgen Inc.
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (USD Billion), 2021
14.1.3.2. Amgen Inc. 2021 Osteoporosis Treatment Business Regional Distribution
14.1.4. Product /Service and Specification
14.1.5. Recent Developments & Business Strategy
14.2. Asahi Kasei Corporation
14.3. DAIICHI SANKYO COMPANY, LIMITED
14.4. Dr. Reddy’s Laboratories Ltd.
14.5. Eli Lilly and Company
14.6. F. Hoffmann-La Roche Ltd
14.7. GSK plc.
14.8. Ligand Pharmaceuticals Incorporated
14.9. Merck & Co., Inc.
14.10. Novartis AG
14.11. Pfizer Inc.
14.12. Teva Pharmaceutical Industries Ltd.
14.13. Viatris Inc.
